LONDON
According to a new report from research firm Technavio, the global SLE drugs market is expected to grow at a CAGR of 22.41% from 2015-2019.
About the Report
SLE, or lupus, is a chronic autoimmune disease where the immune system attacks and destroys healthy tissues in the body, including the skin, heart, lungs, kidneys, joints, and nervous system.
An increase in the prevalence of this and other autoimmune disorders is expected to contribute to growth in the SLE drugs market.
“Growing prevalence of autoimmune disease has led to the introduction of favorable government initiatives like the Affordable Care Act,” says Faisal Ghaus, Vice President of Technavio.
According to the latest report by Technavio, knowledge about the diagnosis of Systemic Lupus Erythematosus (SLE) and its treatment is growing in Europe and Asia—areas where the disease is more prevalent. Additionally, numerous public campaigns aimed at increasing awareness levels are also being conducted.
“The Lupus Foundation of America has been implementing various projects to increase federal support for lupus research and services for assisting people and families affected by it,” says Ghaus.
Market Scope and Calculation of Market Size
This report covers the present scenario and the growth prospects of the global SLE drugs market from 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of SLE.
Key Information Covered in the Report:
- Key Vendors:
- BMS Co.
- GSK plc
- ImmuPharma plc
- Merck Serono SA
- UCB SA
- Market Growth Drivers:
- High prevalence of autoimmune diseases
- For a full detailed list, view our report.
- Market Challenges:
- Complex etiology
- For a full detailed list, view our report.
- Market Trends:
- Increase in awareness
- For a full detailed list, view our report.
Technavio currently has more than 3000 market research reports on a huge range of topics, including 200+ reports on the drugs market:
If you are interested in more information, please contact our media team at media@technavio.com.
CONTACT
Technavio Research
Jes Ellacott
US: +1 630 333 9501
UK:
+44 208 123 1770
Media & Marketing Executive
www.technavio.com
media@technavio.com
